Tam Elias, Choo Jane Pang Suan, Rao Parinitha, Webb William Richard, Carruthers Jean D A, Rahman Eqram
EHA Clinic, Singapore, Singapore.
The Skin Address, Aesthetic Dermatology Practice, Bengaluru, India.
Aesthetic Plast Surg. 2024 Dec 24. doi: 10.1007/s00266-024-04627-5.
Aesthetic medicine has evolved towards minimally invasive procedures, with biostimulators like Poly-L-Lactic Acid (PLLA), Calcium Hydroxylapatite (CaHA), and Polycaprolactone (PCL) gaining attention for their role in collagen induction, improving skin texture, elasticity, and volume. Combining these agents with other treatments-such as botulinum toxin, dermal fillers, and energy-based devices (e.g. laser and radiofrequency therapies)-is hypothesised to provide enhanced aesthetic outcomes. However, studies on the efficacy and safety of these combinations remain sparse and methodologically varied, posing challenges in establishing definitive recommendations.
This systematic review adhered to PRISMA guidelines, involving a thorough literature search across PubMed, MEDLINE, Embase, and Cochrane databases. The search included terms related to biostimulators and combination treatments. Studies meeting inclusion criteria reported clinical outcomes of combined biostimulator treatments, including effectiveness, safety, patient satisfaction, and adverse effects. Key parameters extracted included treatment area, combination protocols, and outcomes. Data synthesis used a narrative approach due to variability in methodologies, treatment protocols, and outcome metrics.
Out of 1,237 studies initially identified, 29 met the inclusion criteria. These studies included various combinations of biostimulators with botulinum toxin, dermal fillers, and energy-based devices, with sample sizes ranging from 10 to 350 subjects. Treatments combining CaHA or PLLA with energy-based modalities like high-intensity focused ultrasound (HIFU), fractional lasers, and microneedling demonstrated notable improvements in skin texture, elasticity, and contouring, particularly in areas with ageing signs. Adverse events included erythema, bruising, and nodules in 15-30% of cases, with rare but severe complications such as granulomas and vascular occlusions. Management protocols for these events involved corticosteroids, hyaluronidase, or surgical intervention. The review also found a lack of molecular understanding of the synergistic mechanisms.
The review underscores the potential benefits of combined treatments in aesthetic outcomes, though limitations like heterogeneous methodologies, small sample sizes, and inconsistent protocols impact the reliability of findings. Current literature lacks a molecular understanding of the mechanisms underlying these combinations, limiting insights into the longevity and safety of results. Future studies with standardised protocols, objective outcome measures, and detailed molecular analyses are essential for developing evidence-based recommendations for combining biostimulators with other treatments in aesthetic practice.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
美容医学已朝着微创程序发展,聚左旋乳酸(PLLA)、羟基磷灰石钙(CaHA)和聚己内酯(PCL)等生物刺激剂因其在胶原蛋白诱导、改善皮肤质地、弹性和体积方面的作用而受到关注。将这些制剂与其他治疗方法(如肉毒杆菌毒素、真皮填充剂和基于能量的设备,如激光和射频疗法)相结合,据推测可提供更好的美容效果。然而,关于这些联合治疗的疗效和安全性的研究仍然很少,且方法各异,这给制定明确的建议带来了挑战。
本系统评价遵循PRISMA指南,对PubMed、MEDLINE、Embase和Cochrane数据库进行了全面的文献检索。检索词包括与生物刺激剂和联合治疗相关的术语。符合纳入标准的研究报告了联合生物刺激剂治疗的临床结果,包括有效性、安全性、患者满意度和不良反应。提取的关键参数包括治疗区域、联合方案和结果。由于方法、治疗方案和结果指标的差异,数据综合采用了叙述性方法。
在最初确定的1237项研究中,29项符合纳入标准。这些研究包括生物刺激剂与肉毒杆菌毒素、真皮填充剂和基于能量的设备的各种组合,样本量从10到350名受试者不等。将CaHA或PLLA与高强度聚焦超声(HIFU)、分数激光和微针等基于能量的方式相结合的治疗,在皮肤质地、弹性和轮廓塑造方面显示出显著改善,尤其是在有衰老迹象的区域。不良事件包括15%至30%的病例出现红斑、瘀伤和结节,还有罕见但严重的并发症,如肉芽肿和血管阻塞。针对这些事件的处理方案包括使用皮质类固醇、透明质酸酶或手术干预。该综述还发现对协同机制缺乏分子层面的理解。
该综述强调了联合治疗在美容效果方面的潜在益处,尽管方法学异质性、样本量小和方案不一致等局限性影响了研究结果的可靠性。目前的文献缺乏对这些联合治疗潜在机制的分子层面理解,限制了对结果的持久性和安全性的深入了解。未来采用标准化方案、客观结果测量和详细分子分析的研究,对于在美容实践中为生物刺激剂与其他治疗方法的联合应用制定循证建议至关重要。
证据水平IV:本刊要求作者为每篇文章指定证据水平。有关这些循证医学评级的完整描述,请参阅目录或作者在线指南www.springer.com/00266 。